Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,736 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04855695RecruitingPhase 1/Phase 2
Study for relapsed mantle cell lymphoma using targeted oral drugs
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Chicago, IllinoisAges 18 years+ - NCT04881240RecruitingPhase 1
Donor-made memory T-cell therapy for hard-to-treat leukemia
This Phase 1 study tests an immune-cell therapy made from a matched donor to treat relapsed or refractory CD19-positive leukemia. It may help patients who have limited options, especially those who cannot receive the standard donor-cell or self-made (autologous) CD19 CAR T-cell therapy.
Memphis, TennesseeAges Up to 21 years - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT05302037RecruitingPhase 1
CAR T cell therapy for advanced cancers that can be targeted
This early-phase study tests a lab-made immune cell treatment that is designed to find and attack tumors that show a specific target on cancer cells. It is for adults with advanced cancers that have not responded well to at least two standard treatments.
SingaporeAges 21 years+ - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT05580601RecruitingPhase 1/Phase 2
Immunotherapy trial for children with relapsed or stubborn AML
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
Cincinnati, OhioAges 2 years+ - NCT05623982RecruitingPhase 1/Phase 2
Study drug for lymphoma that has returned or did not respond
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
Beijing, Beijing MunicipalityAges 18–75 - NCT05626400Recruiting
CAR T for relapsed T-ALL or T-LBL with CD7
This trial tests a type of immune therapy (CAR T cells) called Senl-T7 in people whose T-cell leukemia or lymphoma has come back or did not respond. It aims to target cancer cells that carry a marker called CD7.
Beijingcun, HebeiAges 2–70 - NCT05846763Recruiting
Obinutuzumab plus lenalidomide for returning follicular lymphoma
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
TianjinAges 18 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT06066203RecruitingPhase 1/Phase 2
Study of GNC-035 for lymphoma that returned or didn't respond to treatment
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–75 - NCT06197672RecruitingPhase 1
CAR T cells for CD4-positive AML before stem cell transplant
This trial tests a new type of immunotherapy (CAR T cells) designed to target and kill leukemia cells that have a specific marker (CD4). The goal is to help people with acute myeloid leukemia (AML) that has not responded to standard treatments get ready for a stem cell transplant.
Miami, FloridaAges 12 years+ - NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06450067Recruiting
Inaticabtagene Autoleucel for Relapsed or Refractory ALL
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06452732Recruiting
Leukemia stem cell test for AML relapse in children
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06541327Recruiting
Cell therapy for returning lymphoma study
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
ShanghaiAges 18 years+ - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06642025RecruitingEarly Phase 1
EX02 car-t cells for hard-to-treat acute myeloid leukemia
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
Hefei, AnhuiAges 18–70 - NCT06644443RecruitingPhase 1/Phase 2
BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Shenzhen, GuangdongAges 18–75 - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,736 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.